Health technology assessment (HTA) bodies and payers are often frustrated by what they see as a lack of clarity in the approved indications of new medicines, which can make it difficult for them to take appropriate decisions on drug reimbursement.
That was one of the issues broached at a panel session during the recent Drug Information Association Europe 2020 conference, where attendees also heard about problems that HTA bodies experience...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?